Articles
-
2 months ago |
endpts.com | Reynald Castaneda
Sanofi is likely to increase its M&A this year since it has more cash in its pockets, as the French pharma also monitors China as …Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
-
Nov 20, 2024 |
endpts.com | Reynald Castaneda
Novartis is buying gene therapy and neuroscience biotech Kate Therapeutics in a deal worth $1.1 billion in upfront and milestone payments, the Swiss pharma confirmed …Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
-
Sep 15, 2024 |
endpts.com | Reynald Castaneda
BARCELONA — In a result that’s likely to change how some bladder cancer patients get care, AstraZeneca said that its drug Imfinzi boosted patient survival alongside …Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
-
Aug 18, 2024 |
finance.yahoo.com | Reynald Castaneda
Impact on CytoDyn's Clinical Development StrategyNeed to know:GlobalData’s Investigative News team reviews data generated by an in-house model that combines machine learning and its proprietary algorithm. Likelihood of Approval (LoA) provides the probability of a drug in securing market authorization; Phase Transition Success Rate (PTSR) indicates the probability of a drug advancing to the next stage of development.
-
Aug 18, 2024 |
finance.yahoo.com | Reynald Castaneda
Cosentyx vs Humira: Hidradenitis Suppurativa and Current Treatments Need to know: Analysts forecast that the global hidradenitis suppurativa market may garner sales of $763.6m in 2021, with a compound annual growth rate of 4.2% up to 2023 Moderate-to-severe patients have varying efficacy milage with Humira, underscoring the need for more biologic options Candidates Cosentyx and bimekizumab are possible contenders with Phase III trials underway Remicade, which is not approved, might be the...
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →Coverage map
X (formerly Twitter)
- Followers
- Tweets
- DMs Open
RT @RLCscienceboss: Join me Wednesday, March 26 for @endpts inaugural science-focused event, Endpoints Catalysts, where I'll be interviewin…
RT @JohnCendpts: Man, I would really love to know the terms of the deal $SMMT hammered out in partnering with $PFE on its ADCs. Nobody know…
RT @AndrewE_Dunn: Will CRISPR matter? @RLCscienceboss captures the confusing energy of the gene-editing field today: scientific advances, b…
